Navigation Links
Clinical Update - Debio 025 in Hepatitis C
Date:4/28/2008

Presentation of Phase IIa Efficacy Results

LAUSANNE, Switzerland, April 28 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist focusing on serious medical conditions, particularly oncology, presented positive efficacy results of a phase IIa study with Debio 025, a selective cyclophilin (Cyp) inhibitor with a potent in-vitro and in-vivo anti-hepatitis C (HCV) effect. Data indicates that Debio 025 shows an important additive anti-HCV effect when co-administered with pegylated Interferon (Peg-IFN) alpha-2a to treatment- naive HCV patients. Debiopharm presented these findings at the 43rd Annual Meeting of the European Association for the Study of the Liver, in Milan, Italy.

The double-blind, placebo-controlled study investigated different dose regimens of Debio 025 in combination with alpha-2a Peg-IFN 180 Mug/week in treatment naive chronic HCV mono-infected patients. Ninety patients were randomised to receive either of the following treatment regimens during 29 days: Peg-IFN with placebo; Peg-IFN with Debio 025 200 mg/day; Peg-IFN with Debio 025 600 mg/day; Peg-IFN with Debio 025 1000 mg/day; and Debio 025 1000 mg/day.

In patients with genotypes 1 and 4, at day 29, the HCV-RNA reduction was -4.6 log10 IU/mL in the Peg-IFN with Debio 025 600 mg/day arm, and -4.8 log10 IU/mL in the Debio 025 1000 mg/day arm. This was significantly different (p< 0.05) from the Peg-IFN with placebo, as well as the Debio 025 1000 mg/day monotherapy arms, in which the reduction in viral load was respectively -2.49 and -2.20. In these two arms, at day 29, the proportion of subjects with undetectable viral load was 25%. This number increased to 66% in the Peg-IFN with Debio 025 1000 mg/day group.

"To obtain these exciting results after an administration period of only one month is promising and demonstrates that Debio 025 will be a breakthrough in the treatment of HCV infections," said Kame
'/>"/>

SOURCE The Debiopharm Group
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema
2. ESBATechs Lead Antibody Fragment Enters Clinical Development for Ophthalmic Indications
3. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
4. More Clinical Data Required to Support European Approval of CAP Indication for TYGACIL
5. PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy
6. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
7. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
8. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
9. BrainCells Inc. Initiates Phase 2 Clinical Trial with BCI-540 for Depression with Anxiety
10. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
11. AlphaVax Announces Initial Analysis of Data From CMV Phase 1 Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... -- CVS Health Corporation (NYSE: CVS ) will ... 2015, at 8:30 a.m. (EDT) with analysts and investors ... An audio webcast of the conference call will be ... CVS Health website for all interested parties. To access ... be archived and available on the web site for ...
(Date:4/17/2015)... , April 17, 2015 ... EGFR mutation   is a viable alternative to tumour biopsy ... testing in all patients with advanced NSCLC   ... effectiveness of plasma circulating tumour DNA (ctDNA) testing for epidermal ... with advanced non-small cell lung cancer (NSCLC) in clinical practice. ...
(Date:4/17/2015)... , Apr. 17, 2015 Research and Markets ... the "Mammography Equipment - Global Strategic Business Report" ... analyzes the worldwide markets for Mammography Equipment in US$ ... and Digital Mammography Equipment. The report provides separate comprehensive ... Japan , Europe ...
Breaking Medicine Technology:"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 2"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 3"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 4Mammography Equipment (Analog & Digital) Market 2015-2020 - Global Strategic Business Report: Breast Imaging Screening Programs Push Sales 2
... BioVex Inc, a company developing next generation biologics ... announced today that the results from a Phase I/II combination ... will be presented at the 2009 American Society of Clinical ... 2009 - June 2, 2009 in Orlando, FL. The results ...
... on BIBW 2992, an Irreversible, Dual EGFR / HER2 ... NSCLC Patients with EGFR Activating Mutations - (1,2)-The First ... Conn., May 14 Boehringer Ingelheim will present new ... 2992 and BIBF 1120 at the 2009 Annual Meeting ...
Cached Medicine Technology:BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting 2BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting 3BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting 4Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 2Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 3Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 4Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 5Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 6Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 7Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 8Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 9Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 10
(Date:4/18/2015)... (PRWEB) April 18, 2015 “ ArcAngel ” ... which takes a look at the latest and coolest ... Joe Troohey, the host of AppWatch and technology expert, conducted ... a personal safety app. , In a turbulent world, ... help. Calling 911 should always be their first move, but ...
(Date:4/17/2015)... Heritage Woods of McLeansboro, a Gardant affordable ... Celebration on April 20 with a day full of ... and soul. , The community, which is located at ... of all incomes, including those on Medicaid, who need ... Week is observed every April and highlights the communities ...
(Date:4/17/2015)... April 17, 2015 ERGO-Pedic Products, LLC, ... introducing two new products to help a broader range ... pain relief are the second most common visitors to ... product, designed specifically to help relieve sitting pain. Then, ... and thousands of happy customers later, we began getting ...
(Date:4/17/2015)... Florida Hospital Wesley Chapel, Florida Hospital at ... were all selected as Top Workplaces in Tampa Bay. ... is ranked number one for large businesses according to ... in partnership with an independent research firm. Florida Hospital ... opened in October of 2012 with a vision of ...
(Date:4/17/2015)... In Defense of Christians (IDC) Executive Director ... April 15th, the European Parliament joined its voice with ... Armenian Genocide, “paying tribute, on the eve of the ... Armenian victims who perished in the Ottoman Empire.” ... this timely and needed recognition of a tragic episode ...
Breaking Medicine News(10 mins):Health News:A Personal Safety Application was Featured on NewsWatch Television 2Health News:Heritage Woods of McLeansboro Affordable Assisted Living to Celebrate Supportive Living Week 2Health News:Heritage Woods of McLeansboro Affordable Assisted Living to Celebrate Supportive Living Week 3Health News:Seat Cushion Company Credits Customer Driven Design For Two New Products 2Health News:Tampa Bay Times Selects Florida Hospital Wesley Chapel, Florida Hospital at Connerton Long Term Acute Care and Florida Hospital Carrollwood As Top Workplaces in Tampa Bay 2Health News:Tampa Bay Times Selects Florida Hospital Wesley Chapel, Florida Hospital at Connerton Long Term Acute Care and Florida Hospital Carrollwood As Top Workplaces in Tampa Bay 3Health News:Tampa Bay Times Selects Florida Hospital Wesley Chapel, Florida Hospital at Connerton Long Term Acute Care and Florida Hospital Carrollwood As Top Workplaces in Tampa Bay 4Health News:In Defense of Christians Condemns Armenian Genocide 2Health News:In Defense of Christians Condemns Armenian Genocide 3
... system of this mosquito is of great importance as scientists ... of viruses that cause yellow and dengue fevers ... genes that make up the immune system of the Aedes ... been identified. ,This study is the first of ...
... the airplane, is about to be connected, allowing travellers to ... off cell phones and fasten seatbelts are a familiar ... European company has found a way to make dialling safe ... ,"Cabin connectivity is here and GSM phone use is both ...
... a healthy diet rich in fish and nuts could be ... to prostate cancer, new US research indicates . A study ... Investigation found that omega-3 fatty acids found in the foods ... to the condition. Working with mice genetically engineered to develop ...
... an ancient retrovirus that infected chimps and other primates millions ... species is susceptible to HIV, said a study released Thursday. ... against a four-million-year-old virus, called Pan troglodytes endogenous retrovirus, or ... most retroviruses, it inserts its DNA into the genome of ...
... urate in the blood is linked to a reduced risk ... at the Harvard School of Public Health (HSPH), was led ... ,Urate is a normal component of blood, and although ... beneficial effects because it is a potent antioxidant. ...
... Thursday said that all villages affected by chikungunya fever ... spread awareness among people even as 17,000 suspected ... this year. ,'We have asked the nine chikungunya-affected ... National Rural Health Mission, we will provide Rs.10,000 each ...
Cached Medicine News:Health News:Aedes Agypti Mosquitos Immune System Revealed 2Health News:'Hi, can You Hear Me? I'm at 30,000 Feet' 2Health News:'Hi, can You Hear Me? I'm at 30,000 Feet' 3Health News:Ancient Viral Defense may Explain Susceptibility to HIV: Study 2Health News:High Urate Levels in Blood Linked to Reduced Parkinson's Risk 2Health News:Chikungunya-hit Villages to Get Funds to Fight Mosquitoes 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: